AbbVie has announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...
3d
AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated ...
ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met ...
AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in ...
AbbVie Submits BLA To FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer
(RTTNews) - AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated approval of telisotuzumab vedotin (Teliso-V ...
- Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. - Biologics ...
The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing ...
About Telisotuzumab Vedotin (Teliso-V)Teliso-V is an investigational, first-in-class, c-Met protein directed antibody-drug conjugate (ADC) designed to target c-Met overexpressing tumors.
The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback